drugset / Trial / NCT02204839

Combined Basal-bolus Insulin and Post-exercise Carbohydrate Feeding Strategy in T1DM

NCT02204839

NaSingle-groupOpen-labelBasic science

Summary

The investigators hypothesise that reducing basal insulin dose (Glargine, Lantus, Sanofi-Aventis, or Detemir, Levemir, Novo Nordisk), whilst employing current carbohydrate feeding and rapid-acting insulin dose recommendations will protect patients with type 1 diabetes from early- and late-onset hypoglycaemia following evening time exercise.

Timeline

Start
2014-01
Primary completion
2015-01
Completion
2015-01

Drugs

EvaluationDrugModalityDoseRoute
Subject insulin detemir Protein / enzyme biologic
Subject insulin glargine Protein / enzyme biologic